JOURNAL HOME CME HOME THIS MONTH PAST ISSUES ETOC COLLECTIONS AUTHORS REVIEWERS EDITORIAL BOARD FEEDBACK RSS HELP
		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (29) Citing Articles via Google Scholar Google Scholar Articles by Kranke, P. Articles by Eberhart, L. H. Search for Related Content PubMed PubMed Citation Articles by Kranke, P. Articles by Eberhart, L. H. Related Collections Postanesthetic Care Unit Pharmacology

---

ANESTHETIC PHARMACOLOGY

The Efficacy and Safety of Transdermal Scopolamine for the Prevention of Postoperative Nausea and Vomiting: A Quantitative Systematic Review

Peter Kranke, MD^*, Astrid M. Morin, MD, DEAA, Norbert Roewer, MD, PhD^*, Hinnerk Wulf, MD, PhD, and Leopold H. Eberhart, MD

*Department of Anesthesiology, University of Würzburg; and Department of Anesthesiology, University of Marburg, Germany

Address correspondence and reprint requests to Peter Kranke, MD, Department of Anesthesiology, University of Würzburg, Josef-Schneider-Str. 2, D-97080 Würzburg, Germany. Address e-mail to peter.kranke{at}mail.uni-wuerzburg.de

The role of scopolamine administered via transdermal therapeutic systems in the prevention of postoperative vomiting, nausea, and nausea and vomiting is unclear. We performed a systematic search for full reports of randomized comparisons of transdermal scopolamine with inactive control. Dichotomous data were extracted. In the meta-analysis, relative risks and numbers-needed-to-treat/harm were calculated with 95% confidence intervals (CI). In 23 trials, 979 patients received transdermal scopolamine, and 984 patients received placebo. Sensitivity analyses were performed using restricted data for truncated control event rates (40%–80%) and for large trials. With these data, the relative risks for postoperative vomiting (five reports), nausea (five reports), nausea and vomiting (eight reports), and rescue treatment (three reports) were 0.69 (95% CI, 0.58–0.82), 0.69 (95% CI, 0.54–0.87), 0.76 (95% CI, 0.66–0.88), and 0.68 (95% CI, 0.54–0.85), respectively. This means that of 100 patients who receive transdermal scopolamine, approximately 17 will not experience postoperative vomiting who would have done so had they all received a placebo. However, 18 of 100 patients will have visual disturbances, eight will report dry mouth, two will report dizziness, one will be classified as being agitated, and 1–13 patients who are prescribed transdermal scopolamine will not use it correctly. The timing of application does not alter efficacy.

IMPLICATIONS:Of 100 patients who receive transdermal scopolamine, approximately 17 will not vomit in the postoperative period who would have done so had they all received a placebo. However, 18 of 100 patients will have visual disturbances, and eight will report dry mouth. Incorrect use further limits its efficacy.

This article has been cited by other articles:

				T. J. Gan, A. C. Sinha, A. L. Kovac, R. K. Jones, S. A. Cohen, J. P. Battikha, J. S. Deutsch, J. V. Pergolizzi Jr, the TDS Study Group, and P. S. A. Glass A Randomized, Double-Blind, Multicenter Trial Comparing Transdermal Scopolamine Plus Ondansetron to Ondansetron Alone for the Prevention of Postoperative Nausea and Vomiting in the Outpatient Setting Anesth. Analg., May 1, 2009; 108(5): 1498 - 1504. [Abstract] [Full Text] [PDF]

				R. Kapoor, E. T. Hola, R. T. Adamson, and A. S. Mathis Comparison of two instruments for assessing risk of postoperative nausea and vomiting Am. J. Health Syst. Pharm., March 1, 2008; 65(5): 448 - 453. [Abstract] [Full Text] [PDF]

				T. J. Gan, T. A. Meyer, C. C. Apfel, F. Chung, P. J. Davis, A. S. Habib, V. D. Hooper, A. L. Kovac, P. Kranke, P. Myles, et al. Society for Ambulatory Anesthesia Guidelines for the Management of Postoperative Nausea and Vomiting Anesth. Analg., December 1, 2007; 105(6): 1615 - 1628. [Abstract] [Full Text] [PDF]

				P. F. White, J. Tang, D. Song, J. E. Coleman, R. H. Wender, B. Ogunnaike, A. Sloninsky, R. Kapu, M. Shah, and T. Webb Transdermal Scopolamine: An Alternative to Ondansetron and Droperidol for the Prevention of Postoperative and Postdischarge Emetic Symptoms Anesth. Analg., January 1, 2007; 104(1): 92 - 96. [Abstract] [Full Text] [PDF]

				S. M Wilhelm, M. L Dehoorne-Smith, and P. B Kale-Pradhan Prevention of Postoperative Nausea and Vomiting Ann. Pharmacother., January 1, 2007; 41(1): 68 - 78. [Abstract] [Full Text] [PDF]

				J. Golembiewski, E. Chernin, and T. Chopra Prevention and treatment of postoperative nausea and vomiting Am. J. Health Syst. Pharm., June 15, 2005; 62(12): 1247 - 1260. [Abstract] [Full Text] [PDF]

				P. Kranke, A. M. Morin, N. Roewer, and L. H. Eberhart Patients' Global Evaluation of Analgesia and Safety of Injected Parecoxib for Postoperative Pain: A Quantitative Systematic Review Anesth. Analg., September 1, 2004; 99(3): 797 - 806. [Abstract] [Full Text] [PDF]

				T. J. Gan, T. Meyer, C. C. Apfel, F. Chung, P. J. Davis, S. Eubanks, A. Kovac, B. K. Philip, D. I. Sessler, J. Temo, et al. Consensus Guidelines for Managing Postoperative Nausea and Vomiting Anesth. Analg., July 1, 2003; 97(1): 62 - 71. [Abstract] [Full Text] [PDF]

				T. T. Horlocker, M. D. Abel, J. M. Messick Jr, and D. R. Schroeder Small Risk of Serious Neurologic Complications Related to Lumbar Epidural Catheter Placement in Anesthetized Patients Anesth. Analg., June 1, 2003; 96(6): 1547 - 1552. [Abstract] [Full Text] [PDF]

Anesthesia & Analgesia® is published for the International Anesthesia Research Society® by Lippincott Williams & Wilkins with the assistance of Stanford University Libraries' HighWire Press®. Copyright 2006 by the International Anesthesia Research Society. Online ISSN: 1526-7598   Print ISSN: 0003-2999